Table 2.
Baseline characteristics of group 2 eligible but not enrolled versus group 2 women at first antenatal care visit
| Group 2 eligible N=718 |
P value | ||
| Not enrolled N=167* |
Enrolled N=551 |
||
| Age, years | 0.274 | ||
| <24 | 37 (22) | 92 (17) | |
| 25–29 | 44 (26) | 156 (28) | |
| >30 | 86 (52) | 303 (55) | |
| Median | 30 (25–33) | 30 (26–34) | |
| Height, cm | 0.395 | ||
| ≤155 | 53 (32) | 166 (33) | |
| 156–161 | 54 (32) | 191 (35) | |
| ≥162 | 33 (20) | 145 (26) | |
| Missing | 27 (16) | 49 (9) | |
| Median | 157 (153–161) | 158 (154–162) | |
| Body mass index, kg/m2 | 0.920 | ||
| Underweight (<18.5) | 1 (0.01) | 5 (0.01) | |
| Normal (18.5–24.9) | 32 (19) | 103 (19) | |
| Overweight (25.0–29.9) | 35 (21) | 134 (24) | |
| Obese (>30.0) | 71 (43) | 255 (46) | |
| Missing | 28 (17) | 54 (10) | |
| Median | 30 (25–34) | 30 (25–36) | |
| Gravidity | 0.204 | ||
| 1 | 35 (21) | 90 (16) | |
| 2 | 57 (34) | 184 (33) | |
| ≥3 | 67 (40) | 263 (48) | |
| Missing | 8 (5) | 14 (3) | |
| Median | 2 (2–3) | 2 (2–3) | |
| Parity | 0.290 | ||
| 0 | 48 (29) | 129 (23) | |
| 1 | 62 (37) | 222 (40) | |
| ≥2 | 49 (29) | 185 (34) | |
| Missing | 8 (5) | 15 (3) | |
| Median | 1 (0–2) | 1 (1–2) | |
| Previous preterm† | 0.100 | ||
| Yes | 9 (6) | 52 (9) | |
| Haemoglobin g/dL | 0.084 | ||
| Normal (≥11.0) | 46 (28) | 232 (42) | |
| Mild anaemia (9–10.9) | 44 (26) | 153 (28) | |
| Moderate anaemia (7–8.9) | 11 (7) | 26 (5) | |
| Severe anaemia (<7) | 0 | 0 | |
| Missing | 66 (40) | 140 (25) | |
| ART status | 0.577 | ||
| Initiated before pregnancy | 55 (92) | 290 (53) | |
| Initiated during pregnancy | 75 (45) | 261 (47) | |
| Gestational age assessment | |||
| LMP | 148 (89) | 481 (87) | 0.648 |
| Median (weeks) | 13 (10–17) | 13 (9–17) | |
| SFH | 87 (57) | 258 (47) | 0.232 |
| Median (weeks) | 17 (14–20) | 17 (14–20) | |
| US | 167 (100) | 551 (100) | |
| Median (weeks) | 14 (10–18) | 13 (10–17) | |
n (%).
*Eligible for group 2 based on US, but not enrolled into group 2.
†Among women with a previous pregnancy.
ART, antiretroviral therapy; LMP, last menstrual period; SFH, symphysis fundal height; US, ultrasound.